Strategies to relieve immunosuppression in pancreatic cancer

Papers of special note have been highlighted as: • of interest; •• of considerable interest.

References

• 1 Wolfgang CL, Herman JM, Laheru DA et al. Recent progress in pancreatic cancer. CA Cancer J. Clin. 63(5), 318–348 (2013).
  MedlineGoogle Scholar
• 2 Mazur PK, Siveke JT. Genetically engineered mouse models of pancreatic cancer: unravelling tumour biology and progressing translational oncology. Gut 61(10), 1488–1500 (2012).
  MedlineGoogle Scholar
• 3 Robert C, Thomas L, Bondarenko I et al. Ipilimumab plus dacarbazine for previously untreated metastatic melanoma. N. Engl. J. Med. 364(26), 2517–2526 (2011).
  Medline CASGoogle Scholar
• 4 Topalian SL, Hodi FS, Brahmer JR et al. Safety, activity, and immune correlates of anti-PD-1 antibody in cancer. N. Engl. J. Med. 366(26), 2443–2454 (2012).
  Medline CASGoogle Scholar
• 5 Zheng L, Xue J, Jaffee EM, Habtezion A. Role of immune cells and immune-based therapies in pancreatitis and pancreatic ductal adenocarcinoma. Gastroenterology 144(6), 1230–1240 (2013).
  MedlineGoogle Scholar
• 6 Shibuya KC, Goel VK, Xiong W et al. Pancreatic ductal adenocarcinoma contains an effector and regulatory immune cell infiltrate that is altered by multimodal neoadjuvant treatment. PLoS ONE 9(5), e96565 (2014).
  MedlineGoogle Scholar
• 7 Wormann SM, Diakopoulos KN, Lesina M, Algul H. The immune network in pancreatic cancer development and progression. Oncogene 33(23), 2956–2967 (2014).
  Medline CASGoogle Scholar
• 8 Sideras K, Braat H, Kwekkeboom J et al. Role of the immune system in pancreatic cancer progression and immune modulating treatment strategies. Cancer Treat Rev. 40(4), 513–522 (2014).
  Medline CASGoogle Scholar
• 9 Salman B, Zhou D, Jaffee EM, Edil BH, Zheng L. Vaccine therapy for pancreatic cancer. Oncoimmunology 2(12), e26662 (2013).
  MedlineGoogle Scholar
• 10 Bauer C, Dauer M, Saraj S et al. Dendritic cell-based vaccination of patients with advanced pancreatic carcinoma: results of a pilot study. Cancer Immunol. Immunother. 60(8), 1097–1107 (2011).
  Medline CASGoogle Scholar
• 11 Shindo Y, Hazama S, Maeda Y et al. Adoptive immunotherapy with MUC1-mRNA transfected dendritic cells and cytotoxic lymphocytes plus gemcitabine for unresectable pancreatic cancer. J. Transl. Med. 12, 175 (2014).
  MedlineGoogle Scholar
• 12 Weden S, Klemp M, Gladhaug IP et al. Long-term follow-up of patients with resected pancreatic cancer following vaccination against mutant K-ras. Int. J. Cancer 128(5), 1120–1128 (2011).
  Medline CASGoogle Scholar
• 13 Inman KS, Francis AA, Murray NR. Complex role for the immune system in initiation and progression of pancreatic cancer. World J. Gastroenterol. 20(32), 11160–11181 (2014).
  MedlineGoogle Scholar
• 14 Neesse A, Michl P, Frese KK et al. Stromal biology and therapy in pancreatic cancer. Gut 60(6), 861–868 (2011).
  MedlineGoogle Scholar
• 15 Rhim AD, Oberstein PE, Thomas DH et al. Stromal elements act to restrain, rather than support, pancreatic ductal adenocarcinoma. Cancer Cell 25(6), 735–747 (2014).
  Medline CASGoogle Scholar
• 16 Ozdemir BC, Pentcheva-Hoang T, Carstens JL et al. Depletion of carcinoma-associated fibroblasts and fibrosis induces immunosuppression and accelerates pancreas cancer with reduced survival. Cancer Cell 25(6), 719–734 (2014).
  Medline CASGoogle Scholar
• 17 Suso EM, Dueland S, Rasmussen AM et al. hTERT mRNA dendritic cell vaccination: complete response in a pancreatic cancer patient associated with response against several hTERT epitopes. Cancer Immunol. Immunother. 60(6), 809–818 (2011).
  Medline CASGoogle Scholar
• 18 Lutz E, Yeo CJ, Lillemoe KD et al. A lethally irradiated allogeneic granulocyte-macrophage colony stimulating factor-secreting tumor vaccine for pancreatic adenocarcinoma. A Phase II trial of safety, efficacy, and immune activation. Ann. Surg. 253(2), 328–335 (2011).
  MedlineGoogle Scholar
• 19 Le DT, Lutz E, Uram JN et al. Evaluation of ipilimumab in combination with allogeneic pancreatic tumor cells transfected with a GM-CSF gene in previously treated pancreatic cancer. J. Immunother. 36(7), 382–389 (2013).
  Medline CASGoogle Scholar
• 20 Correale P, Aquino A, Giuliani A et al. Treatment of colon and breast carcinoma cells with 5-fluorouracil enhances expression of carcinoembryonic antigen and susceptibility to HLA-A(*)02.01 restricted, CEA-peptide-specific cytotoxic T cells in vitro. Int. J. Cancer. 104(4), 437–445 (2003).
  Medline CASGoogle Scholar
• 21 Bauer C, Bauernfeind F, Sterzik A et al. Dendritic cell-based vaccination combined with gemcitabine increases survival in a murine pancreatic carcinoma model. Gut 56(9), 1275–1282 (2007).
  Medline CASGoogle Scholar
• 22 Bauer C, Sterzik A, Bauernfeind F et al. Concomitant gemcitabine therapy negatively affects DC vaccine-induced CD8(⁺) T-cell and B-cell responses but improves clinical efficacy in a murine pancreatic carcinoma model. Cancer Immunol. Immunother. 63(4), 321–333 (2014).
  Medline CASGoogle Scholar
• 23 Mundy-Bosse BL, Lesinski GB, Jaime-Ramirez AC et al. Myeloid-derived suppressor cell inhibition of the IFN response in tumor-bearing mice. Cancer Res. 71(15), 5101–5110 (2011).
  Medline CASGoogle Scholar
• 24 Kroemer G, Galluzzi L, Kepp O, Zitvogel L. Immunogenic cell death in cancer therapy. Annu. Rev. Immunol. 31, 51–72 (2013).•• This review article highlights how chemotherapeutic drugs mediate so far unrecognized immunological effects via induction of immunogenic forms of tumor cell death ultimately leading to an adaptive immune response against the tumor.
  Medline CASGoogle Scholar
• 25 Dudley ME, Wunderlich JR, Shelton TE, Even J, Rosenberg SA. Generation of tumor-infiltrating lymphocyte cultures for use in adoptive transfer therapy for melanoma patients. J. Immunother. 26(4), 332–342 (2003).
  MedlineGoogle Scholar
• 26 Dudley ME, Yang JC, Sherry R et al. Adoptive cell therapy for patients with metastatic melanoma: evaluation of intensive myeloablative chemoradiation preparative regimens. J. Clin. Oncol. 26(32), 5233–5239 (2008).
  Medline CASGoogle Scholar
• 27 Peiper M, Sato T, Streichert T, Eisenberger CF, Knoefel WT, Izbicki JR. Cytotoxic T lymphocyte mediated recognition of human pancreatic cancer cells. Int. J. Cancer. 99(1), 88–92 (2002).
  Medline CASGoogle Scholar
• 28 Terashima T, Mizukoshi E, Arai K et al. P53, hTERT, WT-1, and VEGFR2 are the most suitable targets for cancer vaccine therapy in HLA-A24 positive pancreatic adenocarcinoma. Cancer Immunol. Immunother. 63(5), 479–489 (2014).
  Medline CASGoogle Scholar
• 29 Abe Y, Ito T, Baba E et al. Nonmyeloablative allogeneic hematopoietic stem cell transplantation as immunotherapy for pancreatic cancer. Pancreas 38(7), 815–819 (2009).
  MedlineGoogle Scholar
• 30 Kanda Y, Komatsu Y, Akahane M et al. Graft-versus-tumor effect against advanced pancreatic cancer after allogeneic reduced-intensity stem cell transplantation. Transplantation 79(7), 821–827 (2005).
  MedlineGoogle Scholar
• 31 Kaneko T, Goto S, Kato A et al. Efficacy of immuno-cell therapy in patients with advanced pancreatic cancer. Anticancer Res. 25(6A), 3709–3714 (2005).
  MedlineGoogle Scholar
• 32 Mukherjee P, Ginardi AR, Madsen CS et al. Mice with spontaneous pancreatic cancer naturally develop MUC-1-specific CTLs that eradicate tumors when adoptively transferred. J. Immunol. 165(6), 3451–3460 (2000).
  Medline CASGoogle Scholar
• 33 Sivinski CL, Kohlgraf KG, Vanlith ML, Morikane K, Tempero RM, Hollingsworth MA. Molecular requirements for CD8-mediated rejection of a MUC1-expressing pancreatic carcinoma: implications for tumor vaccines. Cancer Immunol. Immunother. 51(6), 327–340 (2002).
  Medline CASGoogle Scholar
• 34 Schmitz-Winnenthal FH, Volk C, Z'graggen K et al. High frequencies of functional tumor-reactive T cells in bone marrow and blood of pancreatic cancer patients. Cancer Res. 65(21), 10079–10087 (2005).
  Medline CASGoogle Scholar
• 35 Urba WJ. At the bench: adoptive cell therapy for melanoma. J. Leukoc. Biol. 95(6), 867–874 (2014).
  MedlineGoogle Scholar
• 36 Urba WJ, Longo DL. Redirecting T cells. N. Engl. J. Med. 365(8), 754–757 (2011).
  Medline CASGoogle Scholar
• 37 Abate-Daga D, Lagisetty KH, Tran E et al. A Novel chimeric antigen receptor against prostate stem cell antigen mediates tumor destruction in a humanized mouse model of pancreatic cancer. Human Gene Ther. 25(12), 1003–1012 (2014).
  Medline CASGoogle Scholar
• 38 Chmielewski M, Hahn O, Rappl G et al. T cells that target carcinoembryonic antigen eradicate orthotopic pancreatic carcinomas without inducing autoimmune colitis in mice. Gastroenterology 143(4), 1095–1107 e1092 (2012).
  Medline CASGoogle Scholar
• 39 Hekele A, Dall P, Moritz D et al. Growth retardation of tumors by adoptive transfer of cytotoxic T lymphocytes reprogrammed by CD44v6-specific scFv:zeta-chimera. Int. J. Cancer. 68(2), 232–238 (1996).
  Medline CASGoogle Scholar
• 40 Groth A, Salnikov AV, Ottinger S et al. New gene-immunotherapy combining TRAIL-lymphocytes and EpCAMxCD3 Bispecific antibody for tumor targeting. Clin. Cancer Res. 18(4), 1028–1038 (2012).
  Medline CASGoogle Scholar
• 41 Chen Y, Ayaru L, Mathew S, Morris E, Pereira SP, Behboudi S. Expansion of anti-mesothelin specific CD4⁺ and CD8⁺ T cell responses in patients with pancreatic carcinoma. PLoS ONE 9(2), e88133 (2014).
  MedlineGoogle Scholar
• 42 Mccarty TM, Liu X, Sun JY, Peralta EA, Diamond DJ, Ellenhorn JD. Targeting p53 for adoptive T-cell immunotherapy. Cancer Res. 58(12), 2601–2605 (1998).
  Medline CASGoogle Scholar
• 43 Schmidt J, Ryschich E, Sievers E, Schmidt-Wolf IG, Buchler MW, Marten A. Telomerase-specific T-cells kill pancreatic tumor cells in vitro and in vivo. Cancer 106(4), 759–764 (2006).
  Medline CASGoogle Scholar
• 44 Klug F, Prakash H, Huber PE et al. Low-dose irradiation programs macrophage differentiation to an iNOS(⁺)/M1 phenotype that orchestrates effective T cell immunotherapy. Cancer Cell 24(5), 589–602 (2013).• Demonstrates that local tumor irradiation significantly alters the functional profile of infiltrating tumor-associated macrophages thereby releasing the brake of T-cell inhibition in tumors.
  Medline CASGoogle Scholar
• 45 Ene-Obong A, Clear AJ, Watt J et al. Activated pancreatic stellate cells sequester CD8⁺ T cells to reduce their infiltration of the juxtatumoral compartment of pancreatic ductal adenocarcinoma. Gastroenterology 145(5), 1121–1132 (2013).
  Medline CASGoogle Scholar
• 46 Feig C, Jones JO, Kraman M et al. Targeting CXCL12 from FAP-expressing carcinoma-associated fibroblasts synergizes with anti-PD-L1 immunotherapy in pancreatic cancer. Proc. Natl Acad. Sci. USA 110(50), 20212–20217 (2013).• Provides evidence that effectivity of checkpoint inhibition strongly depends on factors in the tumor stroma and that rational combination therapies can overcome this hurdle.
  Medline CASGoogle Scholar
• 47 Moon EK, Carpenito C, Sun J et al. Expression of a functional CCR2 receptor enhances tumor localization and tumor eradication by retargeted human T cells expressing a mesothelin-specific chimeric antibody receptor. Clin. Cancer Res. 17(14), 4719–4730 (2011).
  Medline CASGoogle Scholar
• 48 Olive KP, Jacobetz MA, Davidson CJ et al. Inhibition of Hedgehog signaling enhances delivery of chemotherapy in a mouse model of pancreatic cancer. Science 324(5933), 1457–1461 (2009).
  Medline CASGoogle Scholar
• 49 Ribas A. Tumor immunotherapy directed at PD-1. N. Engl. J. Med. 366(26), 2517–2519 (2012).
  Medline CASGoogle Scholar
• 50 Perez-Gracia JL, Labiano S, Rodriguez-Ruiz ME, Sanmamed MF, Melero I. Orchestrating immune check-point blockade for cancer immunotherapy in combinations. Curr. Opin. Immunol. 27, 89–97 (2014).
  Medline CASGoogle Scholar
• 51 Hamid O, Robert C, Daud A et al. Safety and tumor responses with lambrolizumab (anti-PD-1) in melanoma. N. Engl. J. Med. 369(2), 134–144 (2013).
  Medline CASGoogle Scholar
• 52 Loos M, Giese NA, Kleeff J et al. Clinical significance and regulation of the costimulatory molecule B7-H1 in pancreatic cancer. Cancer Lett. 268(1), 98–109 (2008).
  Medline CASGoogle Scholar
• 53 Yamato I, Sho M, Nomi T et al. Clinical importance of B7-H3 expression in human pancreatic cancer. Br. J. Cancer 101(10), 1709–1716 (2009).
  Medline CASGoogle Scholar
• 54 Yang M, Sun T, Zhou Y et al. The functional cytotoxic T lymphocyte-associated Protein 4 49G-to-A genetic variant and risk of pancreatic cancer. Cancer 118(19), 4681–4686 (2012).
  Medline CASGoogle Scholar
• 55 Sandin LC, Eriksson F, Ellmark P, Loskog AS, Totterman TH, Mangsbo SM. Local CTLA4 blockade effectively restrains experimental pancreatic adenocarcinoma growth in vivo. Oncoimmunology 3(1), e27614 (2014).
  MedlineGoogle Scholar
• 56 Royal RE, Levy C, Turner K et al. Phase 2 trial of single agent Ipilimumab (anti-CTLA-4) for locally advanced or metastatic pancreatic adenocarcinoma. J. Immunother. 33(8), 828–833 (2010).
  Medline CASGoogle Scholar
• 57 Brahmer JR, Tykodi SS, Chow LQ et al. Safety and activity of anti-PD-L1 antibody in patients with advanced cancer. N. Engl. J. Med. 366(26), 2455–2465 (2012).
  Medline CASGoogle Scholar
• 58 Von Hoff DD, Ramanathan RK, Borad MJ et al. Gemcitabine plus nab-paclitaxel is an active regimen in patients with advanced pancreatic cancer: a Phase I/II trial. J. Clin. Oncol. 29(34), 4548–4554 (2011).
  Medline CASGoogle Scholar
• 59 Stromnes IM, Brockenbrough JS, Izeradjene K et al. Targeted depletion of an MDSC subset unmasks pancreatic ductal adenocarcinoma to adaptive immunity. Gut 63(11), 1769–1781 (2014).
  Medline CASGoogle Scholar
• 60 Rakoff-Nahoum S, Medzhitov R. Toll-like receptors and cancer. Nat. Rev. Cancer 9(1), 57–63 (2009).
  Medline CASGoogle Scholar
• 61 Takeuchi O, Akira S. Pattern recognition receptors and inflammation. Cell 140(6), 805–820 (2010).
  Medline CASGoogle Scholar
• 62 Vaz J, Andersson R. Intervention on toll-like receptors in pancreatic cancer. World J. Gastroenterol. 20(19), 5808–5817 (2014).
  MedlineGoogle Scholar
• 63 Ochi A, Nguyen AH, Bedrosian AS et al. MyD88 inhibition amplifies dendritic cell capacity to promote pancreatic carcinogenesis via Th2 cells. J. Exp. Med. 209(9), 1671–1687 (2012).
  Medline CASGoogle Scholar
• 64 Ochi A, Graffeo CS, Zambirinis CP et al. Toll-like receptor 7 regulates pancreatic carcinogenesis in mice and humans. J. Clin. Invest. 122(11), 4118–4129 (2012).• Challenges the view that TLR ligands mediate antitumor immunity via induction of innate and adaptive immune responses, but may rather promote carcinogenesis via driving proinflammatory responses.
  Medline CASGoogle Scholar
• 65 Hamzah J, Altin JG, Herringson T et al. Targeted liposomal delivery of TLR9 ligands activates spontaneous antitumor immunity in an autochthonous cancer model. J. Immunol. 183(2), 1091–1098 (2009).
  Medline CASGoogle Scholar
• 66 Jacobs C, Duewell P, Heckelsmiller K et al. An ISCOM vaccine combined with a TLR9 agonist breaks immune evasion mediated by regulatory T cells in an orthotopic model of pancreatic carcinoma. Int. J. Cancer. 128(4), 897–907 (2011).
  Medline CASGoogle Scholar
• 67 Pratesi G, Petrangolini G, Tortoreto M et al. Therapeutic synergism of gemcitabine and CpG-oligodeoxynucleotides in an orthotopic human pancreatic carcinoma xenograft. Cancer Res. 65(14), 6388–6393 (2005).
  Medline CASGoogle Scholar
• 68 Van Den Boorn JG, Hartmann G. Turning tumors into vaccines: co-opting the innate immune system. Immunity 39(1), 27–37 (2013).
  Medline CASGoogle Scholar
• 69 Schmidt A, Rothenfusser S, Hopfner KP. Sensing of viral nucleic acids by RIG-I: from translocation to translation. Eur. J. Cell Biol. 91(1), 78–85 (2012).
  Medline CASGoogle Scholar
• 70 Tormo D, Checinska A, Alonso-Curbelo D et al. Targeted activation of innate immunity for therapeutic induction of autophagy and apoptosis in melanoma cells. Cancer Cell 16(2), 103–114 (2009).
  Medline CASGoogle Scholar
• 71 Besch R, Poeck H, Hohenauer T et al. Proapoptotic signaling induced by RIG-I and MDA-5 results in type I interferon-independent apoptosis in human melanoma cells. J. Clin. Invest. 119(8), 2399–2411 (2009).
  Medline CASGoogle Scholar
• 72 Bhoopathi P, Quinn BA, Gui Q et al. Pancreatic cancer-specific cell death induced in vivo by cytoplasmic-delivered polyinosine-polycytidylic acid. Cancer Res. 74(21), 6224–6235 (2014).
  Medline CASGoogle Scholar
• 73 Ellermeier J, Wei J, Duewell P et al. Therapeutic efficacy of bifunctional siRNA combining TGF-beta1 silencing with RIG-I activation in pancreatic cancer. Cancer Res. 73(6), 1709–1720 (2013).• Provides proof-of-concept that RLR ligands can be exploited for immunotherapy of pancreatic cancer and a rationale for the development of bifunctional siRNAs that combine RIG-I activation with RNAi-mediated silencing of immunosuppressive factors.
  Medline CASGoogle Scholar
• 74 Duewell P, Steger A, Lohr H et al. RIG-I-like helicases induce immunogenic cell death of pancreatic cancer cells and sensitize tumors toward killing by CD8(⁺) T cells. Cell Death Differ. 21(12), 1825–1837 (2014).
  Medline CASGoogle Scholar
• 75 Goldeck M, Schlee M, Hartmann G, Hornung V. Enzymatic synthesis and purification of a defined RIG-I ligand. Methods Mol. Biol. 1169, 15–25 (2014).
  Medline CASGoogle Scholar
• 76 Kurahara H, Shinchi H, Mataki Y et al. Significance of M2-polarized tumor-associated macrophage in pancreatic cancer. J. Surg. Res. 167(2), e211–e219 (2011).
  MedlineGoogle Scholar
• 77 Ohki S, Shibata M, Gonda K et al. Circulating myeloid-derived suppressor cells are increased and correlate to immune suppression, inflammation and hypoproteinemia in patients with cancer. Oncol. Rep. 28(2), 453–458 (2012).
  MedlineGoogle Scholar
• 78 Ruffell B, Affara NI, Coussens LM. Differential macrophage programming in the tumor microenvironment. Trends Immunol. 33(3), 119–126 (2012).
  Medline CASGoogle Scholar
• 79 Gabrilovich DI, Ostrand-Rosenberg S, Bronte V. Coordinated regulation of myeloid cells by tumours. Nat Rev Immunol. 12(4), 253–268 (2012).
  Medline CASGoogle Scholar
• 80 Pylayeva-Gupta Y, Lee KE, Hajdu CH, Miller G, Bar-Sagi D. Oncogenic Kras-induced GM-CSF production promotes the development of pancreatic neoplasia. Cancer Cell 21(6), 836–847 (2012).
  Medline CASGoogle Scholar
• 81 Bayne LJ, Beatty GL, Jhala N et al. Tumor-derived granulocyte-macrophage colony-stimulating factor regulates myeloid inflammation and T cell immunity in pancreatic cancer. Cancer Cell 21(6), 822–835 (2012).•• Elegant study that shows how pancreatic cancers induce an immunosuppressive microenvironment via recruitment of myeloid cells to the tumor, thereby keeping T-effector cells dysfunctional.
  Medline CASGoogle Scholar
• 82 Kraman M, Bambrough PJ, Arnold JN et al. Suppression of antitumor immunity by stromal cells expressing fibroblast activation protein-alpha. Science 330(6005), 827–830 (2010).
  Medline CASGoogle Scholar
• 83 Beatty GL, Chiorean EG, Fishman MP et al. CD40 agonists alter tumor stroma and show efficacy against pancreatic carcinoma in mice and humans. Science 331(6024), 1612–1616 (2011).•• Very good example of how unexpected results from clinical trials can stimulate fascinating preclincial work (‘from clinic to benchside’) to address novel mechanism of action.
  Medline CASGoogle Scholar
• 84 Kuhnemuth B, Muhlberg L, Schipper M et al. CUX1 modulates polarization of tumor-associated macrophages by antagonizing NF-kappaB signaling. Oncogene 34(2), 177–187 (2013).
  MedlineGoogle Scholar
• 85 Ries CH, Cannarile MA, Hoves S et al. Targeting tumor-associated macrophages with anti-CSF-1R antibody reveals a strategy for cancer therapy. Cancer Cell 25(6), 846–859 (2014).
  Medline CASGoogle Scholar
• 86 Munn DH, Mellor AL. Indoleamine 2,3 dioxygenase and metabolic control of immune responses. Trends Immunol. 34(3), 137–143 (2013).
  Medline CASGoogle Scholar
• 87 Koblish HK, Hansbury MJ, Bowman KJ et al. Hydroxyamidine inhibitors of indoleamine-2,3-dioxygenase potently suppress systemic tryptophan catabolism and the growth of IDO-expressing tumors. Mol Cancer Ther. 9(2), 489–498 (2010).
  Medline CASGoogle Scholar
• 88 Lauber K, Ernst A, Orth M, Herrmann M, Belka C. Dying cell clearance and its impact on the outcome of tumor radiotherapy. Front. Oncol. 2, 116 (2012).
  MedlineGoogle Scholar
• 89 Burnette BC, Liang H, Lee Y et al. The efficacy of radiotherapy relies upon induction of type i interferon-dependent innate and adaptive immunity. Cancer Res. 71(7), 2488–2496 (2011).
  Medline CASGoogle Scholar
• 90 Hennel R, Brix N, Seidl K et al. Release of monocyte migration signals by breast cancer cell lines after ablative and fractionated gamma-irradiation. Radiat. Oncol. 9(1), 85 (2014).
  MedlineGoogle Scholar
• 91 Formenti SC, Demaria S. Radiation therapy to convert the tumor into an in situ vaccine. Int. J. Radiat. Oncol. Biol. Phys. 84(4), 879–880 (2012).
  MedlineGoogle Scholar
• 92 Shibamoto Y, Nishimura U, Abe M. Intraoperative radiotherapy and hyperthermia for unresectable pancreatic cancer. Hepatogastroenterology 43(8), 326–332 (1996).
  Medline CASGoogle Scholar
• 93 Garcia-Carbonero R, Carnero A, Paz-Ares L. Inhibition of HSP90 molecular chaperones: moving into the clinic. Lancet Oncol. 14(9), e358–369 (2013).
  Medline CASGoogle Scholar
• 94 Milanovic D, Firat E, Grosu AL, Niedermann G. Increased radiosensitivity and radiothermosensitivity of human pancreatic MIA PaCa-2 and U251 glioblastoma cell lines treated with the novel Hsp90 inhibitor NVP-HSP990. Radiat. Oncol. 8, 42 (2013).
  MedlineGoogle Scholar
• 95 Lauber K, Munoz LE, Berens C, Jendrossek V, Belka C, Herrmann M. Apoptosis induction and tumor cell repopulation: the yin and yang of radiotherapy. Radiat. Oncol. 6, 176 (2011).
  MedlineGoogle Scholar
• 96 Hardacre JM, Mulcahy M, Small W et al. Addition of algenpantucel-L immunotherapy to standard adjuvant therapy for pancreatic cancer: a Phase 2 study. J. Gastrointest. Surg. 17(1), 94–100; discussion 100–101 (2013).
  MedlineGoogle Scholar
• 97 Gunturu KS, Rossi GR, Saif MW. Immunotherapy updates in pancreatic cancer: are we there yet? Adv. Med. Oncol. 5(1), 81–89 (2013).
  Medline CASGoogle Scholar
• 98 Deng L, Liang H, Burnette B et al. Irradiation and anti-PD-L1 treatment synergistically promote antitumor immunity in mice. J. Clin. Invest. 124(2), 687–695 (2014).
  Medline CASGoogle Scholar